Zhang Longshan, Fan Yao, Wang Xiaoqing, Yang Mi, Wu XiXi, Huang Weiqiang, Lan Jin, Liao Liwei, Huang Wenqi, Yuan Lu, Pan Hua, Wu Yuting, Chen Longhua, Guan Jian
Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Department of Oncology, The First Hospital of Hebei Medical University, Shijiazhuang, China.
Front Oncol. 2020 Oct 15;10:554331. doi: 10.3389/fonc.2020.554331. eCollection 2020.
Carbohydrate sulfotransferase 4 (CHST4) plays an important role in lymphocyte homing and is abnormally expressed in several cancer types; however, its precise function in tumor development and progression is unknown. Here we confirm that CHST4 is aberrantly expressed in various tumor subtypes. In particular, we found that CHST4 expression was downregulated in hepatitis B virus-related hepatocellular carcinoma (HBV-HCC) tumors compared to paired normal tissue. We also showed that CHST4 overexpression inhibited the proliferation and metastasis of HCC cells . Clinically, CHST4 was identified as an independent prognostic factor for HBV-HCC patients. We further illuminated the anti-tumor role and mechanism of CHST4 in HBV-HCC by constructing a FENDRR-miR-10b-5p-CHST4 competing endogenous RNA network. We found that downregulation of CHST4 expression may promote HBV expression and regulate ribonucleoprotein complex biogenesis to promote malignant behaviors in HBV-HCC. CHST4 may also recruit CD4+ T cells, macrophages, dendritic cells, and neutrophils into the tumor microenvironment to inhibit the progression of HBV-HCC. Overall, our findings suggest that CHST4 acts as a tumor suppressor in HCC-HBV and represents a potential diagnostic and therapeutic target.
碳水化合物硫酸转移酶4(CHST4)在淋巴细胞归巢中起重要作用,且在几种癌症类型中异常表达;然而,其在肿瘤发生和发展中的精确功能尚不清楚。在此,我们证实CHST4在各种肿瘤亚型中异常表达。特别是,我们发现与配对的正常组织相比,CHST4在乙型肝炎病毒相关肝细胞癌(HBV-HCC)肿瘤中的表达下调。我们还表明,CHST4过表达抑制了肝癌细胞的增殖和转移。临床上,CHST4被确定为HBV-HCC患者的独立预后因素。我们通过构建FENDRR-miR-10b-5p-CHST4竞争性内源RNA网络,进一步阐明了CHST4在HBV-HCC中的抗肿瘤作用及机制。我们发现,CHST4表达下调可能促进HBV表达,并调节核糖核蛋白复合体生物合成以促进HBV-HCC中的恶性行为。CHST4还可能将CD4+ T细胞、巨噬细胞、树突状细胞和中性粒细胞募集到肿瘤微环境中,以抑制HBV-HCC的进展。总体而言,我们的研究结果表明,CHST4在HCC-HBV中作为肿瘤抑制因子发挥作用,是一个潜在的诊断和治疗靶点。